» Articles » PMID: 31130710

Heterologous Immunity Between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens

Overview
Journal Cells
Publisher MDPI
Date 2019 May 28
PMID 31130710
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Host immune responses play an important role in the outcome of infection with hepatitis C virus (HCV). They can lead to viral clearance and a positive outcome, or progression and severity of chronic disease. Extensive research in the past >25 years into understanding the immune responses against HCV have still resulted in many unanswered questions implicating a role for unknown factors and events. In our earlier studies, we made a surprising discovery that peptides derived from structural and non-structural proteins of HCV have substantial amino acid sequence homologies with various proteins of adenoviruses and that immunizing mice with a non-replicating, non-recombinant adenovirus vector leads to induction of a robust cross-reactive cellular and humoral response against various HCV antigens. In this work, we further demonstrate antibody cross-reactivity between Ad and HCV in vivo. We also extend this observation to show that recombinant adenoviruses containing antigens from unrelated pathogens also possess the ability to induce cross-reactive immune responses against HCV antigens along with the induction of transgene antigen-specific immunity. This cross-reactive immunity can (a) accommodate the making of dual-pathogen vaccines, (b) play an important role in the natural course of HCV infection and (c) provide a plausible answer to many unexplained questions regarding immunity to HCV.

Citing Articles

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice.

Zhu J, He C, Liu Y, Chen M, Zhang J, Chen D Front Microbiol. 2024; 15:1472824.

PMID: 39588106 PMC: 11586386. DOI: 10.3389/fmicb.2024.1472824.


Exploring T-Cell Immunity to Hepatitis C Virus: Insights from Different Vaccine and Antigen Presentation Strategies.

Costa G, Sautto G Vaccines (Basel). 2024; 12(8).

PMID: 39204016 PMC: 11359689. DOI: 10.3390/vaccines12080890.


Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune responses in mice.

Patel R, Agrawal B Front Immunol. 2023; 14:1178523.

PMID: 37334376 PMC: 10272440. DOI: 10.3389/fimmu.2023.1178523.


The use of adenoviral vectors in gene therapy and vaccine approaches.

Araujo N, Rubio I, Toneto N, Morale M, Tamura R Genet Mol Biol. 2022; 45(3 Suppl 1):e20220079.

PMID: 36206378 PMC: 9543183. DOI: 10.1590/1678-4685-GMB-2022-0079.


Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.

Xiao Y, Xu H, Guo W, Zhao Y, Luo Y, Wang M Mol Biomed. 2021; 1(1):16.

PMID: 34765999 PMC: 7711057. DOI: 10.1186/s43556-020-00017-w.


References
1.
Riviere Y, Montange T, Janvier G, Marnata C, Durrieu L, Chaix M . Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection. Virol J. 2012; 9:76. PMC: 3369207. DOI: 10.1186/1743-422X-9-76. View

2.
Bowen D, Walker C . Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005; 436(7053):946-52. DOI: 10.1038/nature04079. View

3.
Pusch E, Renz H, Skevaki C . Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?. Allergo J. 2020; 27(3):28-45. PMC: 7149200. DOI: 10.1007/s15007-018-1580-4. View

4.
Krishnadas D, Li W, Kumar R, Tyrrell L, Agrawal B . In vitro activation and differentiation of naïve CD4+ and CD8+ T cells into HCV core- and NS3-specific armed effector cells: a new role for CD4+ T cells. Cell Immunol. 2009; 259(2):141-9. DOI: 10.1016/j.cellimm.2009.06.009. View

5.
Mina M, Luciani F, Cameron B, Bull R, Beard M, Booth D . Resistance to hepatitis C virus: potential genetic and immunological determinants. Lancet Infect Dis. 2015; 15(4):451-60. DOI: 10.1016/S1473-3099(14)70965-X. View